Canada markets closed

InnoCan Pharma Corporation (INNPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4819-0.0481 (-9.08%)
At close: 01:14PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5300
Open0.4832
BidN/A x N/A
AskN/A x N/A
Day's Range0.4819 - 0.4832
52 Week Range0.2762 - 1.2706
Volume8,000
Avg. Volume3,205
Market Cap113.061M
Beta (5Y Monthly)4.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Innocan Pharma Announces Important Updates Regarding its LPT Platform Project and Commercialization Paths

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - January 20, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to provide an update on its research into CBD loaded liposomes using Innocan's LPT platform. Innocan's core goal is to develop a technology that combines the advantages of two well-known drug and delivery system to create a novel drug product that can be used for vast array of ...

  • GlobeNewswire

    Cannabis Industry Investor Conference: Company Executives Present January 19th & 20th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.comNEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 11:00 AM ET on Wednesday, January 19th. It is recommended that inve

  • Newsfile

    Innocan Pharma Announces the Inauguration of Its Drug Development Lab at Biohouse in the Hadassah Medical Center in Jerusalem

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - January 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has inaugurated its first and new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the Company's liposome Platform Technology (LPT) development. The Company's development program is focused on improving and optimizing LPT characterization met